Skip to Main Content
Breast, Phase II

A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer

What is the purpose of this trial?

This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations.

The names of the study drugs involved in this study are:

  • Niraparib (Zejula)
  • Dostarlimab

Contact Information

For more information about this study, including how to volunteer, contact Mariya Rozenblit

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    04/26/2024
  • Study HIC
    #2000034986